PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35466160-5 2022 While statins and ezetimibe remain first-line treatment, patients often require addition of multiple therapies to achieve goal LDL-C levels. Ezetimibe 18-27 component of oligomeric golgi complex 2 Homo sapiens 127-132 25626487-10 2015 Compared to non-switchers, the adjusted least squares mean differences in the percentage change in LDL-C levels from baseline were 18.74% (p = 0.0003), 16.73% (p < 0.0001), and -0.11% (p = 0.9044) when switching from simvastatin/ezetimibe, rosuvastatin, and atorvastatin, respectively. Ezetimibe 232-241 component of oligomeric golgi complex 2 Homo sapiens 99-104 25626487-11 2015 The odds of LDL-C goal attainment at follow-up among switchers from simvastatin/ezetimibe, rosuvastatin, and atorvastatin were 0.40 (95% CI: 0.23-0.70), 0.36 (95% CI: 0.26-0.51) and 1.03 (95% CI: 0.92-1.15) relative to non-switchers respectively. Ezetimibe 80-89 component of oligomeric golgi complex 2 Homo sapiens 12-17 25626487-12 2015 IMPLICATIONS: Among the high risk CVD population in UK, switching to simvastatin from HET, especially rosuvastatin and simvastatin/ezetimibe, resulted in an increase in LDL-C levels and lower goal attainment. Ezetimibe 131-140 component of oligomeric golgi complex 2 Homo sapiens 169-174 34375677-7 2022 RESULTS: Out of 103 patients 91 were eligible for further evaluation with 31 in group A, 31 in group B, and 29 in group C. The plasma LDL-C levels were reduced only by 33.82% in the Rosuvastatin monotherapy group, 52.13% in the Rosuvastatin/Ezetimibe group, and 73.59% in the Evolocumab/Rosuvastatin/Ezetimibe group (P < 0.0001) at 24 weeks compared to the prior therapy levels. Ezetimibe 241-250 component of oligomeric golgi complex 2 Homo sapiens 134-139 34375677-7 2022 RESULTS: Out of 103 patients 91 were eligible for further evaluation with 31 in group A, 31 in group B, and 29 in group C. The plasma LDL-C levels were reduced only by 33.82% in the Rosuvastatin monotherapy group, 52.13% in the Rosuvastatin/Ezetimibe group, and 73.59% in the Evolocumab/Rosuvastatin/Ezetimibe group (P < 0.0001) at 24 weeks compared to the prior therapy levels. Ezetimibe 300-309 component of oligomeric golgi complex 2 Homo sapiens 134-139 33941059-2 2021 OBJECTIVE: PCSK9 inhibitors have been shown to reduce LDLc by up to about 60% and 85% when used with high doses of statins and ezetimibe (2019 ESC/EAS Guidelines). Ezetimibe 127-136 component of oligomeric golgi complex 2 Homo sapiens 54-58 32072178-4 2020 When maximized use of high-intensity statins followed by add-on therapy with ezetimibe was simulated using a Monte Carlo model, the LDL-C target was reached in 19.9% using high-intensity statin monotherapy and in another 28.5% with high-intensity statins and ezetimibe, while 50.7% would still be eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Ezetimibe 77-86 component of oligomeric golgi complex 2 Homo sapiens 132-137 33738013-1 2021 Background: Adding ezetimibe to high-intensity statin therapy is used for additional lowering of low-density lipoprotein cholesterol (LDL-C); however, there are little data on the efficacy of ezetimibe when combined with a high-intensity statin. Ezetimibe 19-28 component of oligomeric golgi complex 2 Homo sapiens 134-139 33738013-2 2021 A meta-analysis was performed to evaluate the efficacy of ezetimibe added to high-intensity statin therapy on LDL-C levels. Ezetimibe 58-67 component of oligomeric golgi complex 2 Homo sapiens 110-115 33738013-7 2021 Compared to the high-intensity statin monotherapy, the MD in LDL-C reduction with high-intensity statin therapy plus ezetimibe was -14.00% (95% confidence interval: -17.78 to -10.22; P < 0.001) with a moderate degree of heterogeneity (P < 0.001, I2 = 66%). Ezetimibe 117-126 component of oligomeric golgi complex 2 Homo sapiens 61-66 33738013-9 2021 Conclusions: Our study found that adding ezetimibe to high-intensity statin therapy provided a significant but attenuated incremental reduction in LDL-C levels. Ezetimibe 41-50 component of oligomeric golgi complex 2 Homo sapiens 147-152 32072178-4 2020 When maximized use of high-intensity statins followed by add-on therapy with ezetimibe was simulated using a Monte Carlo model, the LDL-C target was reached in 19.9% using high-intensity statin monotherapy and in another 28.5% with high-intensity statins and ezetimibe, while 50.7% would still be eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Ezetimibe 259-268 component of oligomeric golgi complex 2 Homo sapiens 132-137 29910030-7 2018 Bempedoic acid added to background lipid-modifying therapy that included ezetimibe reduced LDL-C by 28.5% more than placebo (p < 0.001; -23.5% bempedoic acid, +5.0% placebo). Ezetimibe 73-82 component of oligomeric golgi complex 2 Homo sapiens 91-96 32202541-2 2020 High levels of LDL cholesterol (LDL-C) represent a causal factor for cardiovascular diseases on an atherosclerotic basis, with a direct correlation between these and mortality or cardiovascular events, such that the reduction of both is associated proportionally and linearly with the reduction of LDL-C.Statins and ezetimibe are used for LDL-C lowering but may not be sufficient to achieve the targets defined by the ESC/EAS guidelines, which recommend use of PCSK9 inhibitors for further LDL-C reduction in patients not at goal.This project submitted 86 clinical scenarios to a group of experts, cardiologists, internists and lipidologists, collecting their opinion on the appropriateness of different behaviors and decisions. Ezetimibe 316-325 component of oligomeric golgi complex 2 Homo sapiens 15-30 32202541-2 2020 High levels of LDL cholesterol (LDL-C) represent a causal factor for cardiovascular diseases on an atherosclerotic basis, with a direct correlation between these and mortality or cardiovascular events, such that the reduction of both is associated proportionally and linearly with the reduction of LDL-C.Statins and ezetimibe are used for LDL-C lowering but may not be sufficient to achieve the targets defined by the ESC/EAS guidelines, which recommend use of PCSK9 inhibitors for further LDL-C reduction in patients not at goal.This project submitted 86 clinical scenarios to a group of experts, cardiologists, internists and lipidologists, collecting their opinion on the appropriateness of different behaviors and decisions. Ezetimibe 316-325 component of oligomeric golgi complex 2 Homo sapiens 32-37 31434507-2 2019 This trial tested whether LDL-C-lowering therapy with ezetimibe is useful for the primary prevention of cardiovascular events in older patients. Ezetimibe 54-63 component of oligomeric golgi complex 2 Homo sapiens 26-31 31434507-3 2019 METHODS: This multicenter, prospective, randomized, open-label, blinded end-point evaluation conducted at 363 medical institutions in Japan examined the preventive efficacy of ezetimibe for patients aged >=75 years, with elevated LDL-C without history of coronary artery disease. Ezetimibe 176-185 component of oligomeric golgi complex 2 Homo sapiens 230-235 31434507-11 2019 CONCLUSIONS: LDL-C-lowering therapy with ezetimibe prevented cardiovascular events, suggesting the importance of LDL-C lowering for primary prevention in individuals aged >=75 years with elevated LDL-C. Ezetimibe 41-50 component of oligomeric golgi complex 2 Homo sapiens 13-18 31434507-11 2019 CONCLUSIONS: LDL-C-lowering therapy with ezetimibe prevented cardiovascular events, suggesting the importance of LDL-C lowering for primary prevention in individuals aged >=75 years with elevated LDL-C. Ezetimibe 41-50 component of oligomeric golgi complex 2 Homo sapiens 113-118 31434507-11 2019 CONCLUSIONS: LDL-C-lowering therapy with ezetimibe prevented cardiovascular events, suggesting the importance of LDL-C lowering for primary prevention in individuals aged >=75 years with elevated LDL-C. Ezetimibe 41-50 component of oligomeric golgi complex 2 Homo sapiens 113-118 31061366-9 2019 The LDL-C control rate at 12 months was significantly higher in the atorvastatin + EZ group compared with the atorvastatin group (p = 0.006). Ezetimibe 83-85 component of oligomeric golgi complex 2 Homo sapiens 4-9 30470229-8 2018 Importantly, the higher rate of achievement of LDL-C goal was attained at group of combination statin with ezetimibe (79.2% in group A20E10 vs 50.0% in group A40, p = 0.016). Ezetimibe 107-116 component of oligomeric golgi complex 2 Homo sapiens 47-52 30470229-10 2018 CONCLUSIONS: In this randomized study, the data showed that a combination of moderate statin and ezetimibe achieved more reduction of LDL-C compared to the double-dose statin but similar impact on inflammation markers. Ezetimibe 97-106 component of oligomeric golgi complex 2 Homo sapiens 134-139 30480766-21 2018 For serum lipids, adding ezetimibe to statin or fenofibrate might further reduce the low-density lipoprotein cholesterol (LDL-C), total cholesterol and triglyceride levels and likely increase the high-density lipoprotein cholesterol levels; however, substantial heterogeneity was detected in most analyses.None of the included studies reported on health-related quality of life. Ezetimibe 25-34 component of oligomeric golgi complex 2 Homo sapiens 85-120 30480766-21 2018 For serum lipids, adding ezetimibe to statin or fenofibrate might further reduce the low-density lipoprotein cholesterol (LDL-C), total cholesterol and triglyceride levels and likely increase the high-density lipoprotein cholesterol levels; however, substantial heterogeneity was detected in most analyses.None of the included studies reported on health-related quality of life. Ezetimibe 25-34 component of oligomeric golgi complex 2 Homo sapiens 122-127 30326894-10 2018 CONCLUSIONS: The overall efficacy and subgroup"s efficacy of combination therapy of Ezetimibe and Atorvastatin on lowering LDL-C, TC and TG was significantly better than Atorvastatin monotherapy"s. Ezetimibe 84-93 component of oligomeric golgi complex 2 Homo sapiens 123-128 30023003-11 2018 Ezetimibe is a cholesterol-lowering drug from the class of cholesterol absorption inhibitors, with the potency to decrease LDL-C by about 10-18% and Apo B by 11-16%, while in combination therapy with statins, an additional LDL-C lowering of 25% or total LDL-C lowering of 34-61% is observed. Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 123-128 30023003-15 2018 Ezetimibe, in combination therapy with a maximal or maximally tolerated statin therapy, is used in patients who fail to achieve target LDL-C levels with statin monotherapy. Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 135-140 30023003-18 2018 Conclusion: Ezetimibe add-on to statin combination therapy is an effective treatment option that leads to additional LDL-C lowering - recommended in situations where, with a maximal or maximally tolerated statin monotherapy treatment regimen, LDL-C targets cannot be achieved. Ezetimibe 12-21 component of oligomeric golgi complex 2 Homo sapiens 117-122 30023003-18 2018 Conclusion: Ezetimibe add-on to statin combination therapy is an effective treatment option that leads to additional LDL-C lowering - recommended in situations where, with a maximal or maximally tolerated statin monotherapy treatment regimen, LDL-C targets cannot be achieved. Ezetimibe 12-21 component of oligomeric golgi complex 2 Homo sapiens 243-248 30023003-11 2018 Ezetimibe is a cholesterol-lowering drug from the class of cholesterol absorption inhibitors, with the potency to decrease LDL-C by about 10-18% and Apo B by 11-16%, while in combination therapy with statins, an additional LDL-C lowering of 25% or total LDL-C lowering of 34-61% is observed. Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 223-228 30023003-11 2018 Ezetimibe is a cholesterol-lowering drug from the class of cholesterol absorption inhibitors, with the potency to decrease LDL-C by about 10-18% and Apo B by 11-16%, while in combination therapy with statins, an additional LDL-C lowering of 25% or total LDL-C lowering of 34-61% is observed. Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 223-228 29038147-0 2018 Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. Ezetimibe 114-123 component of oligomeric golgi complex 2 Homo sapiens 23-38 29857919-12 2018 IMPLICATIONS: Combination therapy of ezetimibe 10 mg with varying doses of rosuvastatin that are commonly used in the clinical field improved the lipid profile and allowed more subjects to reach the LDL-C goal in primary hypercholesterolemia compared with rosuvastatin monotherapy. Ezetimibe 37-46 component of oligomeric golgi complex 2 Homo sapiens 199-204 29396832-1 2018 BACKGROUND AND AIMS: Ezetimibe reduces plasma low-density lipoprotein cholesterol (LDL-C) levels by up to 20%. Ezetimibe 21-30 component of oligomeric golgi complex 2 Homo sapiens 46-81 29396832-1 2018 BACKGROUND AND AIMS: Ezetimibe reduces plasma low-density lipoprotein cholesterol (LDL-C) levels by up to 20%. Ezetimibe 21-30 component of oligomeric golgi complex 2 Homo sapiens 83-88 29805487-12 2018 In conclusion, statins combined with colesevelam or ezetimibe were more effective in reducing plasma LDL-C levels than high-intensity statin monotherapy. Ezetimibe 52-61 component of oligomeric golgi complex 2 Homo sapiens 101-106 28444187-0 2018 Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting. Ezetimibe 57-66 component of oligomeric golgi complex 2 Homo sapiens 75-80 29169939-11 2018 With added ezetimibe 10 mg/d, his LDL-C normalized to 60 mg/dL (-80% further decrease); and his beta-sitosterol decreased to 14.1 mg/L (-68% further decrease). Ezetimibe 11-20 component of oligomeric golgi complex 2 Homo sapiens 34-39 29233637-6 2018 A combination of simvastatin 40 mg daily and ezetimibe 10 mg daily resulted in 57% lowering of LDL-C. Ezetimibe 45-54 component of oligomeric golgi complex 2 Homo sapiens 95-100 29201198-1 2017 Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hsCRP), and the addition of ezetimibe to statins further reduces LDL-C and hsCRP. Ezetimibe 127-136 component of oligomeric golgi complex 2 Homo sapiens 164-169 29255347-13 2017 In the PD assessments, rosuvastatin and ezetimibe monotherapy reduced the LDL-C and TC levels effectively. Ezetimibe 40-49 component of oligomeric golgi complex 2 Homo sapiens 74-79 29172973-1 2017 BACKGROUND: Ezetimibe is recommended by clinical practice guidelines as a second-line therapy for lowering low-density lipoprotein cholesterol (LDL-C) levels, but little is known about its use and effectiveness in real-world populations. Ezetimibe 12-21 component of oligomeric golgi complex 2 Homo sapiens 144-149 29172973-18 2017 CONCLUSIONS: The addition of or switch to ezetimibe therapy was associated with a relatively small percentage of LDL-C goal achievement (< 70 mg/dL) in patients with clinical ASCVD and/or HeFH, even among patients with baseline LDL-C between 70 and 99 mg/dL. Ezetimibe 42-51 component of oligomeric golgi complex 2 Homo sapiens 113-118 29172973-18 2017 CONCLUSIONS: The addition of or switch to ezetimibe therapy was associated with a relatively small percentage of LDL-C goal achievement (< 70 mg/dL) in patients with clinical ASCVD and/or HeFH, even among patients with baseline LDL-C between 70 and 99 mg/dL. Ezetimibe 42-51 component of oligomeric golgi complex 2 Homo sapiens 231-236 29201198-10 2017 In conclusion, the addition of ezetimibe to rosuvastatin was demonstrated to further reduce LDL-C, hsCRP and Lp-PLA2 compared with rosuvastatin monotherapy in patients with AMI. Ezetimibe 31-40 component of oligomeric golgi complex 2 Homo sapiens 92-97 28639183-2 2017 Low-density lipoprotein cholesterol (LDL-C) reduction with statins and ezetimibe has been shown to reduce the risk of cardiovascular events. Ezetimibe 71-80 component of oligomeric golgi complex 2 Homo sapiens 0-35 28750828-11 2017 Two consecutive calculated LDL-C values <25 mg/dl were observed in 28% of alirocumab-treated patients (vs 0.4% with ezetimibe). Ezetimibe 119-128 component of oligomeric golgi complex 2 Homo sapiens 27-32 28599257-6 2017 The odds to treat to LDL-C target was greater for simvastatin-ezetimibe fixed combination, simvastatin, atorvastatin and rosuvastatin, in decreasing order. Ezetimibe 62-71 component of oligomeric golgi complex 2 Homo sapiens 21-26 28430910-2 2017 Methods and results: The HIJ-PROPER study is a prospective, randomized, open-label trial to assess whether intensive LDL-C lowering with standard-dose pitavastatin plus ezetimibe reduces cardiovascular events more than standard LDL-C lowering with pitavastatin monotherapy in patients with acute coronary syndrome (ACS) and dyslipidaemia. Ezetimibe 169-178 component of oligomeric golgi complex 2 Homo sapiens 117-122 28711708-7 2017 Ezetimibe and simvastatin combination treatment lowered fasting total cholesterol, LDLc and Lp(a) concentrations and Apo B/A1 ratio and suppressed the MNC expression of IL-1beta and CD68 (by 21 +- 7 and 24 +- 10, p < 0.05) and the concentrations of LPS, CRP, FFA and IL-18 by 24 +- 7%, 32 +- 11%, 19 +- 8% 15 +- 4%, respectively, (p < 0.05). Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 83-87 28639183-2 2017 Low-density lipoprotein cholesterol (LDL-C) reduction with statins and ezetimibe has been shown to reduce the risk of cardiovascular events. Ezetimibe 71-80 component of oligomeric golgi complex 2 Homo sapiens 37-42 28291866-1 2017 Importance: In the Improved Reduction of Outcomes: Vytorin Efficacy International Trial, intensive low-density lipoprotein cholesterol (LDL-C)-reducing therapy with ezetimibe/simvastatin compared with simvastatin alone was associated with a significant reduction in cardiovascular events in 18 144 patients after acute coronary syndrome. Ezetimibe 165-174 component of oligomeric golgi complex 2 Homo sapiens 136-141 28750477-5 2017 When combined with statins (+- ezetimibe), high rates of LDL-C goal achievement were observed (41%-87% with alirocumab and 63%-100% with evolocumab). Ezetimibe 28-40 component of oligomeric golgi complex 2 Homo sapiens 57-62 28496547-0 2017 Effect of Ezetimibe Monotherapy on Low-Density Lipoprotein Cholesterol and on Markers of Cholesterol Synthesis and Absorption in Japanese Patients With Hypercholesterolemia. Ezetimibe 10-19 component of oligomeric golgi complex 2 Homo sapiens 35-70 28496547-1 2017 BACKGROUND: The aim of this study was to evaluate effect of ezetimibe monotherapy on serum low-density lipoprotein cholesterol (LDL-C) in Japanese patients and to investigate the association between changes of LDL-C and changes of markers for cholesterol synthesis and absorption. Ezetimibe 60-69 component of oligomeric golgi complex 2 Homo sapiens 91-126 28496547-1 2017 BACKGROUND: The aim of this study was to evaluate effect of ezetimibe monotherapy on serum low-density lipoprotein cholesterol (LDL-C) in Japanese patients and to investigate the association between changes of LDL-C and changes of markers for cholesterol synthesis and absorption. Ezetimibe 60-69 component of oligomeric golgi complex 2 Homo sapiens 128-133 28496547-8 2017 CONCLUSION: Ezetimibe monotherapy reduced LDL-C and increased HDL-C, with the reduction of LDL-C being greater in patients with higher levels of cholesterol absorption markers. Ezetimibe 12-21 component of oligomeric golgi complex 2 Homo sapiens 42-47 28496547-8 2017 CONCLUSION: Ezetimibe monotherapy reduced LDL-C and increased HDL-C, with the reduction of LDL-C being greater in patients with higher levels of cholesterol absorption markers. Ezetimibe 12-21 component of oligomeric golgi complex 2 Homo sapiens 91-96 27739167-10 2016 Statin add-on therapies, such as ezetimibe and the recently approved proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors alirocumab and evolocumab, allow patients to achieve very low LDL-C levels and are likely to impact on future treatment paradigms. Ezetimibe 33-42 component of oligomeric golgi complex 2 Homo sapiens 196-201 27531965-1 2017 PURPOSE OF THE STUDY: Statins and ezetimibe reduce low-density lipoprotein cholesterol (LDL-c) and cardiovascular disease (CVD) risk. Ezetimibe 34-43 component of oligomeric golgi complex 2 Homo sapiens 88-93 28647412-7 2017 Among patients who ultimately discontinued vs continued ezetimibe, respective mean LDL-C levels were 79.8 and 78.3 mg/dL 6 months before reporting of the ENHANCE results and 93.5 and 78.1 mg/dL 6 months after reporting of ENHANCE. Ezetimibe 56-65 component of oligomeric golgi complex 2 Homo sapiens 83-88 28647412-8 2017 Predictive application of the Cholesterol Treatment Trialists" meta-analysis suggested the 13.9 mg/dL increase in mean LDL-C translated to a 9.4% increase in relative CVD risk for those who discontinued ezetimibe. Ezetimibe 203-212 component of oligomeric golgi complex 2 Homo sapiens 119-124 27620638-4 2016 The LDL-C target is adjusted to <100 or <70 mg/dL in subjects with coronary artery disease (CAD) with ezetimibe being second line. Ezetimibe 108-117 component of oligomeric golgi complex 2 Homo sapiens 4-9 28506389-9 2017 Patients using ezetimibe monotherapy because of statin intolerance (n = 24, 29%) had less LDL-c decrease compared with patients who concurrently used statin therapy (47% and 58%, P = .03). Ezetimibe 15-24 component of oligomeric golgi complex 2 Homo sapiens 90-95 28647412-0 2017 Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial. Ezetimibe 161-170 component of oligomeric golgi complex 2 Homo sapiens 37-72 26916323-8 2016 Treatment with atorvastatin 40 mg plus ezetimibe 10 mg achieved significantly greater reductions in LDLc (p < 0.001), total cholesterol (p < 0.001) and non-HDLc (p < 0.001). Ezetimibe 39-48 component of oligomeric golgi complex 2 Homo sapiens 100-104 27039291-11 2016 For the mean of weeks 22 and 24, LDL-C level with ezetimibe was 183.0 mg/dL; mean percent LDL-C change, -16.7% (95% CI, -20.5% to -12.9%), absolute change, -31.0 mg/dL and with evolocumab was 103.6 mg/dL; mean percent change, -54.5% (95% CI, -57.2% to -51.8%); absolute change, -106.8 mg/dL (P < .001). Ezetimibe 50-59 component of oligomeric golgi complex 2 Homo sapiens 33-38 27039291-12 2016 LDL-C level at week 24 with ezetimibe was 181.5 mg/dL; mean percent change, -16.7% (95% CI, -20.8% to -12.5%); absolute change, -31.2 mg/dL and with evolocumab was 104.1 mg/dL; mean percent change, -52.8% (95% CI, -55.8% to -49.8%); absolute change, -102.9 mg/dL (P < .001). Ezetimibe 28-37 component of oligomeric golgi complex 2 Homo sapiens 0-5 27039291-17 2016 CONCLUSIONS AND RELEVANCE: Among patients with statin intolerance related to muscle-related adverse effects, the use of evolocumab compared with ezetimibe resulted in a significantly greater reduction in LDL-C levels after 24 weeks. Ezetimibe 145-154 component of oligomeric golgi complex 2 Homo sapiens 204-209 26916323-0 2016 [Utility of treatment with atorvastatin 40 mg plus ezetimibe 10 mg versus atorvastatin 80 mg in reducing the levels of LDL cholesterol in patients with ischaemic stroke or transient ischaemic attack]. Ezetimibe 51-60 component of oligomeric golgi complex 2 Homo sapiens 119-134 26916323-10 2016 CONCLUSIONS: Compared with atorvastatin 80 mg, atorvastatin 40 mg plus ezetimibe 10 mg increases the likelihood of achieving LDLc goals after ischaemic stroke or transient ischaemic attack. Ezetimibe 71-80 component of oligomeric golgi complex 2 Homo sapiens 125-129 26385394-3 2015 This relationship has recently been extended to reduction in LDL-C with a non-statin, ezetimibe, on top of statin therapy, further consolidating LDL-C as the cornerstone in CVD risk reduction. Ezetimibe 86-95 component of oligomeric golgi complex 2 Homo sapiens 61-66 26792014-3 2016 Ezetimibe is a non-statin agent that inhibits intestinal cholesterol absorption, leading to reductions in low-density lipoprotein cholesterol (LDL-C). Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 143-148 26792014-5 2016 In this review, we discuss the findings from these studies as well as potential indications for the use of ezetimibe for LDL-C lowering and cardiovascular event reduction. Ezetimibe 107-116 component of oligomeric golgi complex 2 Homo sapiens 121-126 26638010-7 2016 In the baseline rosuvastatin 10 mg group, significantly greater LDL-C reductions were observed with add-on alirocumab (-50.6%) versus ezetimibe (-14.4%; p < 0.0001) and double-dose rosuvastatin (-16.3%; p < 0.0001). Ezetimibe 134-143 component of oligomeric golgi complex 2 Homo sapiens 64-69 26510755-7 2016 After 10 months of treatment with pitavastatin (2 mg/day) and ezetimibe (10 mg/day), LDL-C decreased from 595 mg/dL to 267 mg/dL in the boy and from 530 mg/dL to 182 mg/dL in the girl. Ezetimibe 62-71 component of oligomeric golgi complex 2 Homo sapiens 85-90 26385394-3 2015 This relationship has recently been extended to reduction in LDL-C with a non-statin, ezetimibe, on top of statin therapy, further consolidating LDL-C as the cornerstone in CVD risk reduction. Ezetimibe 86-95 component of oligomeric golgi complex 2 Homo sapiens 145-150 26169307-10 2015 Addition of ezetimibe to statin therapy has now been shown to decrease levels of low-density lipoprotein (LDL) cholesterol (LDL-C), accompanied by a modest decrease in the number of CV events, though without any improvement in CV mortality. Ezetimibe 12-21 component of oligomeric golgi complex 2 Homo sapiens 124-129 26638446-9 2015 The addition of ezetimibe to simvastatin resulted in an incremental lowering of LDL-C (reached value 53.2 versus 69.9 mg/dl, p < 0.001) and a further improvement of the patient prognosis (relative reduction of primary endpoint: -6.4%, p = 0.016). Ezetimibe 16-25 component of oligomeric golgi complex 2 Homo sapiens 80-85 26638446-11 2015 In acute coronary syndrome, the prescription of ezetimibe should be considered (class HA, level of evidence B) in patients with a LDL-C a 70 mg/dl despite maximally tolerated dose of statin. Ezetimibe 48-57 component of oligomeric golgi complex 2 Homo sapiens 130-135 25037695-7 2014 Least squares mean (SE) LDL-C reductions were 47 (3)% with alirocumab versus 16 (3)% with ezetimibe (ITT; p<0.0001) and 54 (2)% versus 17 (2)% (on-treatment; p<0.0001). Ezetimibe 90-99 component of oligomeric golgi complex 2 Homo sapiens 24-29 25902885-7 2015 Moreover, percent change in PV showed positive correlations with percent change of LDL-C (r = 0.384, P = 0.015).Intensive lipid-lowering therapy with ezetimibe added to usual-dose statin may provide significant incremental reduction in coronary plaques compared with usual-dose statin monotherapy. Ezetimibe 150-159 component of oligomeric golgi complex 2 Homo sapiens 83-88 26089847-5 2015 Those receiving statin + ezetimibe achieved higher rates of LDL-C goal achievement compared with those receiving statin monotherapy (48% vs. 33%, P < 0.05). Ezetimibe 25-34 component of oligomeric golgi complex 2 Homo sapiens 60-65 26134926-1 2015 INTRODUCTION: The combination of ezetimibe and atorvastatin (Liptruzet - referred to in this article as eze/ator), has recently been approved by the FDA for reducing low-density lipoprotein cholesterol (LDL-c) in patients with primary or mixed hyperlipidemia as in case of homozygous familial hypercholesterolemia. Ezetimibe 33-42 component of oligomeric golgi complex 2 Homo sapiens 166-201 26134926-1 2015 INTRODUCTION: The combination of ezetimibe and atorvastatin (Liptruzet - referred to in this article as eze/ator), has recently been approved by the FDA for reducing low-density lipoprotein cholesterol (LDL-c) in patients with primary or mixed hyperlipidemia as in case of homozygous familial hypercholesterolemia. Ezetimibe 33-42 component of oligomeric golgi complex 2 Homo sapiens 203-208 25091271-2 2014 Although both the cholesterol inhibitor ezetimibe and the newer generation bile acid sequestrant colesevelam hydrochloride (HCl) effectively reduce LDL-C levels in patients with hypercholesterolemia, real-world evidence based on clinical outcomes is lacking. Ezetimibe 40-49 component of oligomeric golgi complex 2 Homo sapiens 148-153 25714444-6 2015 During the 12-week ezetimibe treatment period, cholesterol absorption markers significantly decreased, and serum lipid profiles, including LDL-C levels, significantly improved. Ezetimibe 19-28 component of oligomeric golgi complex 2 Homo sapiens 139-144 25714444-7 2015 The LDL-C-lowering rate was greater in those patients who had been receiving statin therapy and were newly started on ezetimibe additionally than in the ezetimibe monotherapy group (-31.4% vs. -18.4%; P<0.001). Ezetimibe 118-127 component of oligomeric golgi complex 2 Homo sapiens 4-9 25714444-7 2015 The LDL-C-lowering rate was greater in those patients who had been receiving statin therapy and were newly started on ezetimibe additionally than in the ezetimibe monotherapy group (-31.4% vs. -18.4%; P<0.001). Ezetimibe 153-162 component of oligomeric golgi complex 2 Homo sapiens 4-9 25463129-6 2014 RESULTS: LDL-C percent change from baseline was -26.0 for ezetimibe added to ongoing statin therapy, -27.6 for switching from ongoing statin to ezetimibe/simvastatin, -19.7 for switching to rosuvastatin 10 mg, and -9.7 for dose doubling of the ongoing statin. Ezetimibe 58-67 component of oligomeric golgi complex 2 Homo sapiens 9-14 25463129-7 2014 For patients within 0.8 mmol/L (30 mg/dL) of the target at baseline, LDL-C target attainment rates were 75.9% for adding ezetimibe to ongoing statin, 72.8% for switching to ezetimibe/simvastatin, 61.8% for switching to rosuvastatin, and 44.3% for statin dose-doubling. Ezetimibe 121-130 component of oligomeric golgi complex 2 Homo sapiens 69-74 25463129-7 2014 For patients within 0.8 mmol/L (30 mg/dL) of the target at baseline, LDL-C target attainment rates were 75.9% for adding ezetimibe to ongoing statin, 72.8% for switching to ezetimibe/simvastatin, 61.8% for switching to rosuvastatin, and 44.3% for statin dose-doubling. Ezetimibe 173-182 component of oligomeric golgi complex 2 Homo sapiens 69-74 24725763-2 2014 Ezetimibe, an inhibitor of the Niemann-Pick C1-Like 1 cholesterol transporter, is a relatively new drug for LDL-C-lowering therapy in addition to statins. Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 108-113 24725763-3 2014 However, comparison between an aggressive LDL-C-lowering therapy with a combination of statin and ezetimibe versus a standard LDL-C-lowering therapy with statin alone is still unclear in terms of their effects on stabilization and volume regression of coronary plaque. Ezetimibe 98-107 component of oligomeric golgi complex 2 Homo sapiens 42-47 24734885-9 2014 A simulation indicated that the combined treatment of ezetimibe with rosuvastatin (2.5 mg day(-1) ) led to superior clinical responses than those with high doses of rosuvastatin (5.0 mg day(-1) ) monotherapy, even in patients with higher baseline LDL-C concentrations prior to the treatment. Ezetimibe 54-63 component of oligomeric golgi complex 2 Homo sapiens 247-252 24308644-10 2014 Use of ezetimibe (10 mg) was strongly associated with meeting LDL-C goals (OR 16.9, p < 0.0001). Ezetimibe 7-16 component of oligomeric golgi complex 2 Homo sapiens 62-67 25089134-9 2014 Ezetimibe added to statin decreased the total cholesterol by 21.1+-7.7% (p<0.001) and the LDL-C by 29.9+-12.6% (p<0.001). Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 93-98 25089134-12 2014 CONCLUSION: A prior inhibition of cholesterol synthesis by statin enhanced the effect of ezetimibe on total cholesterol and LDL-C by 7.8% and 11.2%, respectively. Ezetimibe 89-98 component of oligomeric golgi complex 2 Homo sapiens 124-129 24259646-8 2014 These therapies have been evaluated as monotherapy and in combination with statins and ezetimibe in phase 2 trials and have demonstrated significant and dose-related reductions in LDL-C. Ezetimibe 87-96 component of oligomeric golgi complex 2 Homo sapiens 180-185 24222265-2 2013 Statins, ezetimibe, and bile acid sequestrants significantly lower LDL-c levels in these patients and subsequently markedly improve survival; however, even with these interventions LDL-c goals often are not met. Ezetimibe 9-18 component of oligomeric golgi complex 2 Homo sapiens 67-72 24528691-0 2014 Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. Ezetimibe 60-69 component of oligomeric golgi complex 2 Homo sapiens 116-121 24528691-7 2014 LDL-C reduction from baseline and attainment of LDL-C <100 and <70 mg/dL were substantially greater for patients who switched to ezetimibe/simvastatin therapy (-24.0%, 81.2%, and 35.2%, respectively) than for patients who titrated (-9.6%, 68.0%, and 18.4%, respectively) or remained on initial statin therapy (4.9%, 72.2%, and 23.7%, respectively). Ezetimibe 135-144 component of oligomeric golgi complex 2 Homo sapiens 0-5 24528691-7 2014 LDL-C reduction from baseline and attainment of LDL-C <100 and <70 mg/dL were substantially greater for patients who switched to ezetimibe/simvastatin therapy (-24.0%, 81.2%, and 35.2%, respectively) than for patients who titrated (-9.6%, 68.0%, and 18.4%, respectively) or remained on initial statin therapy (4.9%, 72.2%, and 23.7%, respectively). Ezetimibe 135-144 component of oligomeric golgi complex 2 Homo sapiens 48-53 23603824-0 2013 Differences in action of atorvastatin and ezetimibe in lowering low-density lipoprotein cholesterol and effect on endothelial function: randomized controlled trial. Ezetimibe 42-51 component of oligomeric golgi complex 2 Homo sapiens 64-99 24094079-0 2013 RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale. Ezetimibe 42-51 component of oligomeric golgi complex 2 Homo sapiens 74-79 24094079-3 2013 In this study we seek to demonstrate the superior effect of ezetimibe in combination with strong statins to reduce LDL-C in Japanese patients suffering from both T2DM and hyper LDL-cholesterolemia. Ezetimibe 60-69 component of oligomeric golgi complex 2 Homo sapiens 115-120 24454328-9 2013 CONCLUSIONS: Statin + ezetimibe was the most effective group in lowering TC and LDL-C levels, while niacin + fibrates was the most effective in decreasing TG and increasing HDL-C levels. Ezetimibe 22-31 component of oligomeric golgi complex 2 Homo sapiens 80-85 24265554-0 2013 Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Ezetimibe 72-81 component of oligomeric golgi complex 2 Homo sapiens 11-16 24265554-5 2013 RESULTS: LDL-C reductions from baseline and goal attainment improved substantially in patients treated with ezetimibe added onto simvastatin, atorvastatin, or rosuvastatin therapy (n=2,312) versus those (n=13,053) who titrated these statins. Ezetimibe 108-117 component of oligomeric golgi complex 2 Homo sapiens 9-14 24265554-6 2013 In multivariable models, percent change from baseline in LDL-C was -13.1% to -14.8% greater for those who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin versus those who titrated. Ezetimibe 112-121 component of oligomeric golgi complex 2 Homo sapiens 57-62 24265554-7 2013 The odds of attaining LDL-C<1.8 and <2.6 mmol/L (70 and 100 mg/dL) increased by 2.6-3.2-fold and 2.5-3.1-fold, respectively, in patients who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin versus titrating statins. Ezetimibe 153-162 component of oligomeric golgi complex 2 Homo sapiens 22-27 24265554-8 2013 CONCLUSION: CHD/CHD risk-equivalent patients in a large US managed-care database, who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin, had greater LDL-C reductions and goal attainment than those who uptitrated these statin therapies. Ezetimibe 92-101 component of oligomeric golgi complex 2 Homo sapiens 163-168 24265554-9 2013 Our study suggests that high-risk CHD patients in need of more intensive LDL-C lowering therapy may benefit by adding ezetimibe onto statin therapy. Ezetimibe 118-127 component of oligomeric golgi complex 2 Homo sapiens 73-78 23040830-3 2012 We tested whether ezetimibe added to on-going statin therapy would be most effective in lowering LDL-cholesterol (LDL-C) in subjects on high-potency statins and whether these effects would be related to alterations in cholesterol absorption (beta-sitosterol) and synthesis (lathosterol) markers. Ezetimibe 18-27 component of oligomeric golgi complex 2 Homo sapiens 97-112 23040830-3 2012 We tested whether ezetimibe added to on-going statin therapy would be most effective in lowering LDL-cholesterol (LDL-C) in subjects on high-potency statins and whether these effects would be related to alterations in cholesterol absorption (beta-sitosterol) and synthesis (lathosterol) markers. Ezetimibe 18-27 component of oligomeric golgi complex 2 Homo sapiens 114-119 23040830-8 2012 Ezetimibe treatment in the high-potency group produced significantly greater reductions from baseline in LDL-C than medium-/low-potency groups (-29.1% vs. -25.0% vs. -22.7%; p < 0.001) when evaluating unadjusted data. Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 105-110 23040830-12 2012 Therefore, such patients may be good candidates for ezetimibe therapy if additional LDL-C lowering is needed. Ezetimibe 52-61 component of oligomeric golgi complex 2 Homo sapiens 84-89 22659533-1 2012 AIM: This study compared the effect of doubling the dose of pravastatin with that of adding ezetimibe to low-dose pravastatin on the LDL cholesterol (LDL-C) level and on cholesterol absorption and synthesis markers. Ezetimibe 92-101 component of oligomeric golgi complex 2 Homo sapiens 133-148 22442891-7 2012 The addition of ezetimibe resulted in statistically significant decrease of plasma total cholesterol (TC) (-21%), LDL-C (-28%), triacylglyceroles (TAG) (-26%) and HDL-C (-6%). Ezetimibe 16-25 component of oligomeric golgi complex 2 Homo sapiens 114-119 22442891-13 2012 CONCLUSIONS: The addition of ezetimib in a dose of 10 mg in hyperlipidaemia patients who had not achieved the recommended target values of LDL-C resulted in a subsequent significant decrease of both TC and LDL-C. Ezetimibe 29-37 component of oligomeric golgi complex 2 Homo sapiens 139-144 22442891-13 2012 CONCLUSIONS: The addition of ezetimib in a dose of 10 mg in hyperlipidaemia patients who had not achieved the recommended target values of LDL-C resulted in a subsequent significant decrease of both TC and LDL-C. Ezetimibe 29-37 component of oligomeric golgi complex 2 Homo sapiens 206-211 22659533-1 2012 AIM: This study compared the effect of doubling the dose of pravastatin with that of adding ezetimibe to low-dose pravastatin on the LDL cholesterol (LDL-C) level and on cholesterol absorption and synthesis markers. Ezetimibe 92-101 component of oligomeric golgi complex 2 Homo sapiens 150-155 22659533-8 2012 RESULTS: LDL-C and apo B decreased by 16% and 14% in the ezetimibe add-on group versus 5.9% and 4.4%, respectively, in the pravastatin double-dose group. Ezetimibe 57-66 component of oligomeric golgi complex 2 Homo sapiens 9-14 22659533-14 2012 CONCLUSIONS: Adding ezetimibe to low-dose pravastatin achieves greater decreases in LDL-C, apo B, and cholesterol absorption markers than doubling the dose of pravastatin. Ezetimibe 20-29 component of oligomeric golgi complex 2 Homo sapiens 84-89 21663647-14 2011 The best predictor for LDL-c goal attainment was the use of combined therapy with statin and ezetimibe. Ezetimibe 93-102 component of oligomeric golgi complex 2 Homo sapiens 23-28 22291820-11 2011 CONCLUSIONS: In patients at high CAD risk who are above the LDL-C target while on statin monotherapy, co-administration of ezetimibe is well tolerated and more effective in improving the lipid profile compared to doubling the existing statin dose. Ezetimibe 123-132 component of oligomeric golgi complex 2 Homo sapiens 60-65 21699369-15 2011 CONCLUSIONS: A single tablet combination of 10 mg ezetimibe and 20 mg simvastatin in Taiwanese patients with hypercholesterolemia provided high LDL-C goal attainment rates and resulted in significant reductions in LDL-C. Ezetimibe 50-59 component of oligomeric golgi complex 2 Homo sapiens 144-149 21699369-15 2011 CONCLUSIONS: A single tablet combination of 10 mg ezetimibe and 20 mg simvastatin in Taiwanese patients with hypercholesterolemia provided high LDL-C goal attainment rates and resulted in significant reductions in LDL-C. Ezetimibe 50-59 component of oligomeric golgi complex 2 Homo sapiens 214-219 21349260-0 2011 Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. Ezetimibe 37-46 component of oligomeric golgi complex 2 Homo sapiens 128-143 21349260-4 2011 RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goals (1.81 and 2.59 mmol/L, respectively). Ezetimibe 28-37 component of oligomeric golgi complex 2 Homo sapiens 71-76 21349260-4 2011 RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goals (1.81 and 2.59 mmol/L, respectively). Ezetimibe 28-37 component of oligomeric golgi complex 2 Homo sapiens 157-162 21473671-11 2011 A significantly greater percentage reduction in LDL-C levels was achieved in patients treated with ezetimibe-statin vs statin monotherapy (weighted mean difference [WMD]: -14.1% [-16.1, -12.1], p < 0.001). Ezetimibe 99-108 component of oligomeric golgi complex 2 Homo sapiens 48-53 21473671-12 2011 Reduction in LDL-C levels attributed to add-on ezetimibe was significantly greater than that for statin dose doubling (WMD: -15.3% [-19.1, -11.4], p < 0.001). Ezetimibe 47-56 component of oligomeric golgi complex 2 Homo sapiens 13-18 21473671-15 2011 Results indicate that add-on ezetimibe is significantly more effective in reducing LDL-C levels than doubling statin dose, enabling more patients to achieve LDL-C goal. Ezetimibe 29-38 component of oligomeric golgi complex 2 Homo sapiens 83-88 21473671-15 2011 Results indicate that add-on ezetimibe is significantly more effective in reducing LDL-C levels than doubling statin dose, enabling more patients to achieve LDL-C goal. Ezetimibe 29-38 component of oligomeric golgi complex 2 Homo sapiens 157-162 21497705-3 2011 Data to support the LDL-C lowering efficacy of ezetimibe/simvastatin (EZE/SMV) outside of controlled clinical studies are currently lacking. Ezetimibe 47-56 component of oligomeric golgi complex 2 Homo sapiens 20-25 21519514-2 2011 The aim of this study is to compare the effect of ezetimibe/simvastatin 10/20 mg and atorvastatin 20 mg on achieving a target LDL-C goal in very high risk patients. Ezetimibe 50-59 component of oligomeric golgi complex 2 Homo sapiens 126-131 21519514-11 2011 CONCLUSION: Ezetimibe/simvastatin 10/20 mg and atorvastatin 20 mg showed similar effects in achieving target LDL-C levels in patients with very high risk. Ezetimibe 12-21 component of oligomeric golgi complex 2 Homo sapiens 109-114 21255539-4 2011 The effectiveness of ezetimibe was assessed by determination of total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C) and triglycerides (TR). Ezetimibe 21-30 component of oligomeric golgi complex 2 Homo sapiens 88-103 21255539-4 2011 The effectiveness of ezetimibe was assessed by determination of total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C) and triglycerides (TR). Ezetimibe 21-30 component of oligomeric golgi complex 2 Homo sapiens 105-110 21255539-6 2011 RESULTS: A significant reduction of TC and LDL-C blood levels by 25% and 34% respectively, was observed during the first month of treatment with ezetimibe (p<0.001). Ezetimibe 145-154 component of oligomeric golgi complex 2 Homo sapiens 43-48 21262787-2 2011 Current approaches to reduce circulating LDL-c include statins, which inhibit cholesterol synthesis, and ezetimibe, which blocks cholesterol absorption. Ezetimibe 105-114 component of oligomeric golgi complex 2 Homo sapiens 41-46 20199786-3 2010 Although it is known that an additional reduction of low-density lipoprotein cholesterol (LDL-C) levels can be induced by the combination of ezetimibe with statins, it is not known if this can enhance some pleiotropic effects, which may be useful in slowing the atherosclerotic process. Ezetimibe 141-150 component of oligomeric golgi complex 2 Homo sapiens 90-95 20487050-8 2010 In this group, treatment with ezetimibe/simvastatin 10/40 mg achieved target LDL-C levels in a significantly higher proportion of patients during a 6-week period than switching to either atorvastatin 40 mg or rosuvastatin 5-10 mg. Ezetimibe 30-39 component of oligomeric golgi complex 2 Homo sapiens 77-82 20880342-0 2010 Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events. Ezetimibe 31-40 component of oligomeric golgi complex 2 Homo sapiens 57-62 20075600-3 2010 RESULTS: Compared to the baseline, LDL-C was reduced by 19.2% (p<0.001) after ezetimibe monotherapy and by 24.7% (p<0.001) after co-administration with ezetimibe and any statin. Ezetimibe 81-90 component of oligomeric golgi complex 2 Homo sapiens 35-40 19965915-7 2010 RESULTS: LDL-C levels were reduced by 19% (ezetimibe), 25% (simvastatin), and 41% (ezetimibe+simvastatin) from a baseline of 146 +/- 20 mg/dl; results were similar between ethnic groups. Ezetimibe 43-52 component of oligomeric golgi complex 2 Homo sapiens 9-14 19965915-7 2010 RESULTS: LDL-C levels were reduced by 19% (ezetimibe), 25% (simvastatin), and 41% (ezetimibe+simvastatin) from a baseline of 146 +/- 20 mg/dl; results were similar between ethnic groups. Ezetimibe 83-92 component of oligomeric golgi complex 2 Homo sapiens 9-14 19828909-2 2010 We assessed whether baseline cholesterol absorption markers were associated with response to ezetimibe/simvastatin therapy, in terms of LDL-cholesterol (LDL-C) lowering and cholesterol absorption inhibition, in patients with familial hypercholesterolemia (FH). Ezetimibe 93-102 component of oligomeric golgi complex 2 Homo sapiens 136-151 20075600-3 2010 RESULTS: Compared to the baseline, LDL-C was reduced by 19.2% (p<0.001) after ezetimibe monotherapy and by 24.7% (p<0.001) after co-administration with ezetimibe and any statin. Ezetimibe 158-167 component of oligomeric golgi complex 2 Homo sapiens 35-40 20075600-7 2010 CONCLUSION: Thus, cholesterol absorption inhibition by ezetimibe is an important therapeutic strategy since LDL-C and cholesterol absorption markers had a positive correlation. Ezetimibe 55-64 component of oligomeric golgi complex 2 Homo sapiens 108-113 20155988-6 2010 The main outcome measure was the effect of ezetimibe on low-density lipoprotein cholesterol (LDL-C) and other lipid levels from baseline to 12 weeks. Ezetimibe 43-52 component of oligomeric golgi complex 2 Homo sapiens 56-91 21348380-8 2010 The combination of ezetimibe and low-dose simvastatin significantly reduced levels of total cholesterol (by a mean of 27%), triglycerides (by 9%), and LDL-C (by 33%) and increased levels of high-density lipoprotein cholesterol (by 15%). Ezetimibe 19-28 component of oligomeric golgi complex 2 Homo sapiens 151-156 21090830-16 2010 The addition of ezetimibe to rosuvastatin, simvastatin, or atorvastatin should be the preferred combination therapies when greater LDL-C reductions are required. Ezetimibe 16-25 component of oligomeric golgi complex 2 Homo sapiens 131-136 20155988-6 2010 The main outcome measure was the effect of ezetimibe on low-density lipoprotein cholesterol (LDL-C) and other lipid levels from baseline to 12 weeks. Ezetimibe 43-52 component of oligomeric golgi complex 2 Homo sapiens 93-98 20155988-8 2010 The mean reduction in LDL-C level with ezetimibe monotherapy was significantly greater in patients with impaired LDL-C metabolism, glucose metabolism or hypertension than in those without such abnormalities (-21.0% vs -8.4%, p < 0.01; -22.7% vs -9.5%, p < 0.05; and -22.5% vs -5.9%, p < 0.05; respectively). Ezetimibe 39-48 component of oligomeric golgi complex 2 Homo sapiens 22-27 20155988-9 2010 The reduction in LDL-C levels with ezetimibe monotherapy was also correlated with the number of metabolic abnormalities (rho = 0.426, p = 0.013). Ezetimibe 35-44 component of oligomeric golgi complex 2 Homo sapiens 17-22 20155988-10 2010 CONCLUSIONS: Both ezetimibe monotherapy and combination therapy with ezetimibe and a statin were able to safely and effectively control LDL-C levels in Japanese patients with dyslipidaemia, including those with metabolic abnormalities. Ezetimibe 18-27 component of oligomeric golgi complex 2 Homo sapiens 136-141 20155988-10 2010 CONCLUSIONS: Both ezetimibe monotherapy and combination therapy with ezetimibe and a statin were able to safely and effectively control LDL-C levels in Japanese patients with dyslipidaemia, including those with metabolic abnormalities. Ezetimibe 69-78 component of oligomeric golgi complex 2 Homo sapiens 136-141 20885068-9 2010 A highly significant correlation was observed between alterations in LDL-C and campesterol levels in response to ezetimibe therapy. Ezetimibe 113-122 component of oligomeric golgi complex 2 Homo sapiens 69-74 20885068-6 2010 Compared to baseline values, LDL-cholesterol (LDL-C) was reduced by 24.9% (p<0.005) after 12 weeks of ezetimibe administration. Ezetimibe 105-114 component of oligomeric golgi complex 2 Homo sapiens 29-44 20885068-6 2010 Compared to baseline values, LDL-cholesterol (LDL-C) was reduced by 24.9% (p<0.005) after 12 weeks of ezetimibe administration. Ezetimibe 105-114 component of oligomeric golgi complex 2 Homo sapiens 46-51 19217513-1 2009 Statins, ezetimibe, and bile acid-binding resins can be used individually or in combination for lowering low-density lipoprotein cholesterol (LDL-C) levels. Ezetimibe 9-18 component of oligomeric golgi complex 2 Homo sapiens 105-140 19770669-1 2010 BACKGROUND: Coadministration of any statin with ezetimibe is as effective as using high doses of the same statin in the reduction of low-density lipoprotein cholesterol (LDL-c). Ezetimibe 48-57 component of oligomeric golgi complex 2 Homo sapiens 133-168 19770669-1 2010 BACKGROUND: Coadministration of any statin with ezetimibe is as effective as using high doses of the same statin in the reduction of low-density lipoprotein cholesterol (LDL-c). Ezetimibe 48-57 component of oligomeric golgi complex 2 Homo sapiens 170-175 19262375-5 2009 Ezetimibe, a cholesterol absorption inhibitor, has been shown to be well tolerated and effective in lowering LDL-C. Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 109-114 19262375-6 2009 Adding ezetimibe to ongoing statin therapy leads to a substantial additional reduction in LDL-C, facilitating the achievement of target goals. Ezetimibe 7-16 component of oligomeric golgi complex 2 Homo sapiens 90-95 19262375-7 2009 SUMMARY: The combination of ezetimibe, a cholesterol absorption inhibitor, and statins has been shown to be well tolerated and effective in lowering LDL-C and high-sensitivity C-reactive protein to target goals. Ezetimibe 28-37 component of oligomeric golgi complex 2 Homo sapiens 149-154 19721860-6 2009 RESULTS: Ezetimibe and low-dose simvastatin significantly decreased the levels of total cholesterol (34.6%), triglyceride (16.0%), and low-density lipoprotein cholesterol (LDL-C) (47.6%), and 82.5% of the patients reached the target LDL-C level of <100 mg/dL. Ezetimibe 9-18 component of oligomeric golgi complex 2 Homo sapiens 135-170 19721860-6 2009 RESULTS: Ezetimibe and low-dose simvastatin significantly decreased the levels of total cholesterol (34.6%), triglyceride (16.0%), and low-density lipoprotein cholesterol (LDL-C) (47.6%), and 82.5% of the patients reached the target LDL-C level of <100 mg/dL. Ezetimibe 9-18 component of oligomeric golgi complex 2 Homo sapiens 172-177 19721860-6 2009 RESULTS: Ezetimibe and low-dose simvastatin significantly decreased the levels of total cholesterol (34.6%), triglyceride (16.0%), and low-density lipoprotein cholesterol (LDL-C) (47.6%), and 82.5% of the patients reached the target LDL-C level of <100 mg/dL. Ezetimibe 9-18 component of oligomeric golgi complex 2 Homo sapiens 233-238 19230898-4 2009 RESULTS: After a mean 105 days of treatment with ezetimibe (range, 32-175 days), total cholesterol (TC) levels decreased from 7.3 +/- 1.0 mmol/L to 5.7 +/- 1.0 mmol/L (P < .0001), and low-density lipoprotein cholesterol (LDL-C) levels decreased from 5.3 +/- 0.9 mmol/L to 3.9 +/- 0.8 (P < .0001) in patients with FH. Ezetimibe 49-58 component of oligomeric golgi complex 2 Homo sapiens 187-222 19230898-4 2009 RESULTS: After a mean 105 days of treatment with ezetimibe (range, 32-175 days), total cholesterol (TC) levels decreased from 7.3 +/- 1.0 mmol/L to 5.7 +/- 1.0 mmol/L (P < .0001), and low-density lipoprotein cholesterol (LDL-C) levels decreased from 5.3 +/- 0.9 mmol/L to 3.9 +/- 0.8 (P < .0001) in patients with FH. Ezetimibe 49-58 component of oligomeric golgi complex 2 Homo sapiens 224-229 19230898-9 2009 At a mean of 13.6 months (range, 1-44 months) after the initiation of ezetimibe, LDL-C levels remained decreased at 4.0 +/- 0.6 mmol/L. Ezetimibe 70-79 component of oligomeric golgi complex 2 Homo sapiens 81-86 19230898-10 2009 CONCLUSIONS: In this small retrospective series of children and adolescents with hypercholesterolemia, ezetimibe was safe and effective in lowering LDL-C levels. Ezetimibe 103-112 component of oligomeric golgi complex 2 Homo sapiens 148-153 18353459-3 2009 The co-administration of statins and ezetimibe improved total cholesterol (p<0.05), LDL-c(p<0.05), triglycerides (p<0.05) and apolipoprotein-B (p<0.05) in comparison to statin monotherapy. Ezetimibe 37-46 component of oligomeric golgi complex 2 Homo sapiens 87-92 18353459-5 2009 In conclusion the combination of 10 mg of ezetimibe with high dose statin therapy is effective in hFH, offering a further reduction of LDL-c throughout the 12 months of follow up. Ezetimibe 42-51 component of oligomeric golgi complex 2 Homo sapiens 135-140 19217513-1 2009 Statins, ezetimibe, and bile acid-binding resins can be used individually or in combination for lowering low-density lipoprotein cholesterol (LDL-C) levels. Ezetimibe 9-18 component of oligomeric golgi complex 2 Homo sapiens 142-147 19997842-7 2009 CONCLUSIONS: The fixed combination therapy with ezetimibe/simvastatin showed a clinically significant additional lipid-lowering potential as compared with established statin monotherapies and enabled more patients at cardiovascular risk to reach the LDL-C target level of <100 mg/dl. Ezetimibe 48-57 component of oligomeric golgi complex 2 Homo sapiens 250-255 19192988-12 2009 Patients needing intensive LDL-C lowering to achieve goals will often require adjunctive treatments, including ezetimibe, BARs, or niacin along with statins. Ezetimibe 111-120 component of oligomeric golgi complex 2 Homo sapiens 27-32 18485273-8 2008 For patients not adequately controlled with a statin alone, a meta-analysis of six studies showed that a fixed-dose combination of ezetimibe and statin treatment was associated with a statistically significant reduction in low-density lipoprotein cholesterol (LDL-c) and total cholesterol (Total-c) compared with statin alone (p < 0.00001). Ezetimibe 131-140 component of oligomeric golgi complex 2 Homo sapiens 260-265 21291777-0 2008 Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 102-107 18837641-7 2008 Ezetimibe 10 mg reduced LDL-C by 26.1%, whereas 5 mg reduced LDL-C by 25.8%. Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 24-29 18837641-9 2008 CONCLUSION: These data strongly suggest that ezetimibe 5 mg and ezetimibe 10 mg are clinically equivalent with respect to LDL-C reduction and achievement of ATP III LDL-C goals. Ezetimibe 45-54 component of oligomeric golgi complex 2 Homo sapiens 122-127 18837641-9 2008 CONCLUSION: These data strongly suggest that ezetimibe 5 mg and ezetimibe 10 mg are clinically equivalent with respect to LDL-C reduction and achievement of ATP III LDL-C goals. Ezetimibe 45-54 component of oligomeric golgi complex 2 Homo sapiens 165-170 18485273-10 2008 For patients where a statin is not considered appropriate, a meta-analysis of seven studies demonstrated that ezetimibe monotherapy significantly reduced LDL-c levels compared with placebo (p < 0.00001). Ezetimibe 110-119 component of oligomeric golgi complex 2 Homo sapiens 154-159 18485273-19 2008 CONCLUSIONS: The short-term RCT clinical evidence demonstrated that ezetimibe was effective in reducing LDL-c when administered as monotherapy or in combination with a statin. Ezetimibe 68-77 component of oligomeric golgi complex 2 Homo sapiens 104-109 18485273-20 2008 However, when used as a monotherapy, ezetimibe is less effective than statins in lowering LDL-c. Ezetimibe 37-46 component of oligomeric golgi complex 2 Homo sapiens 90-95 19159125-3 2008 The benefits associated with ezetimibe treatment were informed by a systematic review of clinical evidence and a published relationship linking changes in low-density lipoprotein cholesterol (LDL-C) levels to cardiovascular events. Ezetimibe 29-38 component of oligomeric golgi complex 2 Homo sapiens 155-190 19159125-11 2008 CONCLUSION: Ezetimibe monotherapy compared with no treatment is a cost-effective alternative for individuals with a history of CVD and high LDL-C levels, who do not tolerate statins or in whom they are contraindicated. Ezetimibe 12-21 component of oligomeric golgi complex 2 Homo sapiens 140-145 21291712-0 2008 Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes. Ezetimibe 10-19 component of oligomeric golgi complex 2 Homo sapiens 70-75 19159125-3 2008 The benefits associated with ezetimibe treatment were informed by a systematic review of clinical evidence and a published relationship linking changes in low-density lipoprotein cholesterol (LDL-C) levels to cardiovascular events. Ezetimibe 29-38 component of oligomeric golgi complex 2 Homo sapiens 192-197 19159125-5 2008 A meta-analysis of seven placebo-controlled trials included in the review showed that ezetimibe was associated with a statistically significant mean reduction (from baseline to endpoint) in LDL-C of 18.56% (95% CI -19.68, -17.44; p < 0.00001) compared with placebo. Ezetimibe 86-95 component of oligomeric golgi complex 2 Homo sapiens 190-195 19159125-6 2008 Using 10,000 Monte Carlo simulations, it is estimated that ezetimibe monotherapy would prevent an average of 49 nonfatal myocardial infarctions, 11 nonfatal strokes, and 37 cardiovascular deaths in a cohort of 1,000 patients aged 55 years with a baseline LDL-C concentration of 4.0 mmol/L. Ezetimibe 59-68 component of oligomeric golgi complex 2 Homo sapiens 255-260 18343245-12 2008 NCEP ATP III LDL-C goals were achieved by 87% of patients receiving fluvastatin XL + ezetimibe and 67% of patients receiving fluvastatin XL monotherapy (between-group difference, P = 0.042). Ezetimibe 85-94 component of oligomeric golgi complex 2 Homo sapiens 13-18 18343245-5 2008 The primary end point was the percentage change from baseline to week 12 in LDL-C level with fluvastatin XL + ezetimibe combination therapy compared with fluvastatin XL alone. Ezetimibe 110-119 component of oligomeric golgi complex 2 Homo sapiens 76-81 18343245-10 2008 Fluvastatin XL + ezetimibe and fluvastatin XL monotherapy were associated with significant decreases from baseline in mean LDL-C level (by 49.9% and 35.2%, respectively; between-group difference, P < 0.001). Ezetimibe 17-26 component of oligomeric golgi complex 2 Homo sapiens 123-128 17985033-0 2007 A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. Ezetimibe 124-133 component of oligomeric golgi complex 2 Homo sapiens 69-104 17890931-0 2007 Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors. Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 55-60 17666579-3 2007 OBJECTIVE: To describe the impact of coadministration of ezetimibe with a statin on the estimated 10 year risk for coronary artery disease (E-R(CAD)) in patients with hypercholesterolemia and above-target low-density lipoprotein cholesterol (LDL-C) levels after statin monotherapy. Ezetimibe 57-66 component of oligomeric golgi complex 2 Homo sapiens 205-240 17666579-3 2007 OBJECTIVE: To describe the impact of coadministration of ezetimibe with a statin on the estimated 10 year risk for coronary artery disease (E-R(CAD)) in patients with hypercholesterolemia and above-target low-density lipoprotein cholesterol (LDL-C) levels after statin monotherapy. Ezetimibe 57-66 component of oligomeric golgi complex 2 Homo sapiens 242-247 17666579-12 2007 CONCLUSIONS: For patients with above-target LDL-C levels while on statin monotherapy, coadministration of ezetimibe with the statin is effective in significantly reducing the E-R(CAD). Ezetimibe 106-115 component of oligomeric golgi complex 2 Homo sapiens 44-49 17692154-3 2007 RESULTS: Ezetimibe lowered LDL-C levels by 20-29% across the 3 patient groups after 2-3 months of treatment. Ezetimibe 9-18 component of oligomeric golgi complex 2 Homo sapiens 27-32 17692154-12 2007 Ezetimibe was well tolerated in patients with statin intolerance and was associated with a 26% fall in LDL-C. Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 103-108 17985033-3 2007 RESULTS: In 358 patients, ezetimibe co-administered with ongoing statin therapy significantly reduced the low-density lipoprotein cholesterol (LDL-C) level by an additional 21.9% in the total population. Ezetimibe 26-35 component of oligomeric golgi complex 2 Homo sapiens 106-141 17985033-3 2007 RESULTS: In 358 patients, ezetimibe co-administered with ongoing statin therapy significantly reduced the low-density lipoprotein cholesterol (LDL-C) level by an additional 21.9% in the total population. Ezetimibe 26-35 component of oligomeric golgi complex 2 Homo sapiens 143-148 17985033-6 2007 Ezetimibe co-administered with ongoing statin therapy also increased the number of patients reaching their LDL-C goals according to their risk category (2.5 mmol/l for category 1 patients and 3.0 mmol/l for category 2 patients). Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 107-112 17360295-7 2007 In comparison with baseline, colesevelam HCl-ezetimibe combination therapy was associated with significant reductions in mean levels of total cholesterol (27.5%), LDL-C (42.2%), and non-HDL-C (37.1%). Ezetimibe 45-54 component of oligomeric golgi complex 2 Homo sapiens 163-168 17659159-12 2007 However, the results suggest that ezetimibe co-administered with ongoing statin therapy provides significant additional lipid-lowering in patients not at LDL-C goal on statin therapy alone, allowing more patients to reach their LDL-C goal. Ezetimibe 34-43 component of oligomeric golgi complex 2 Homo sapiens 154-159 17659159-12 2007 However, the results suggest that ezetimibe co-administered with ongoing statin therapy provides significant additional lipid-lowering in patients not at LDL-C goal on statin therapy alone, allowing more patients to reach their LDL-C goal. Ezetimibe 34-43 component of oligomeric golgi complex 2 Homo sapiens 228-233 17451281-2 2007 This study aimed to determine the efficacy and safety of co-administration of the cholesterol absorption inhibitor ezetimibe with an HMG-CoA reductase inhibitor (statin) in the treatment of Mexican patients with dyslipidaemia who had not attained the LDL-C treatment goal with statin monotherapy. Ezetimibe 115-124 component of oligomeric golgi complex 2 Homo sapiens 251-256 17451281-5 2007 RESULTS: Addition of ezetimibe to statin treatment reduced mean serum LDL-C levels significantly (from 160 +/- 42.8 to 100 +/- 36 mg/dL; p<0.001) after 6-8 weeks of treatment, with 61.7% of patients achieving LDL-C values below the goal established according to their coronary risk group. Ezetimibe 21-30 component of oligomeric golgi complex 2 Homo sapiens 70-75 17451281-5 2007 RESULTS: Addition of ezetimibe to statin treatment reduced mean serum LDL-C levels significantly (from 160 +/- 42.8 to 100 +/- 36 mg/dL; p<0.001) after 6-8 weeks of treatment, with 61.7% of patients achieving LDL-C values below the goal established according to their coronary risk group. Ezetimibe 21-30 component of oligomeric golgi complex 2 Homo sapiens 212-217 17451281-8 2007 CONCLUSION: Addition of ezetimibe to statin treatment was both efficacious and safe when used for further reduction of serum LDL-C in dyslipidaemic patients who had not reached their LDL-C treatment goal while taking statin monotherapy. Ezetimibe 24-33 component of oligomeric golgi complex 2 Homo sapiens 125-130 21291692-0 2007 Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia. Ezetimibe 101-110 component of oligomeric golgi complex 2 Homo sapiens 21-56 21291692-4 2007 After 12 weeks, the addition of ezetimibe produced an additional 15% +-9% reduction in LDL-C (P < 0.001) compared to pre-rosuvastatin levels and a mean LDL-C of 103 +- 27 mg/dL, resulting in 59% of patients reaching their LDL-C goals. Ezetimibe 32-41 component of oligomeric golgi complex 2 Homo sapiens 87-92 21291692-4 2007 After 12 weeks, the addition of ezetimibe produced an additional 15% +-9% reduction in LDL-C (P < 0.001) compared to pre-rosuvastatin levels and a mean LDL-C of 103 +- 27 mg/dL, resulting in 59% of patients reaching their LDL-C goals. Ezetimibe 32-41 component of oligomeric golgi complex 2 Homo sapiens 155-160 21291692-4 2007 After 12 weeks, the addition of ezetimibe produced an additional 15% +-9% reduction in LDL-C (P < 0.001) compared to pre-rosuvastatin levels and a mean LDL-C of 103 +- 27 mg/dL, resulting in 59% of patients reaching their LDL-C goals. Ezetimibe 32-41 component of oligomeric golgi complex 2 Homo sapiens 155-160 21291692-9 2007 CONCLUSIONS: The combination of rosuvastatin 40 mg and ezetimibe 10 mg offers the most effective LDL-C-lowering therapy yet reported, and is helpful in achieving lipid goals and reducing C-reactive protein levels in high-risk patients with severe hypercholesterolemia, including familial hypercholesterolemia. Ezetimibe 55-64 component of oligomeric golgi complex 2 Homo sapiens 97-102 17252094-7 2007 DISCUSSION: Changes in LDL-C and goal attainment in Australian general practice with the use of ezetimibe added to a statin were highly consistent with the findings from controlled clinical trials. Ezetimibe 96-105 component of oligomeric golgi complex 2 Homo sapiens 23-28 17360295-10 2007 CONCLUSION: Colesevelam HCl-ezetimibe combination therapy was associated with improved TC, LDL-C, and non-HDL-C lipid profiles and was well tolerated. Ezetimibe 28-37 component of oligomeric golgi complex 2 Homo sapiens 91-96 17036098-2 2006 OBJECTIVES: To assess the effectiveness and safety of ezetimibe 10 mg/day coadministered with a statin in patients with primary hypercholesterolemia who have higher than recommended LDL-C levels while on statin monotherapy. Ezetimibe 54-63 component of oligomeric golgi complex 2 Homo sapiens 182-187 16893434-5 2006 Moreover, a higher proportion of patients on ezetimibe/simvastatin achieved the National Standard Framework LDL-C standard (<3.0 mmol/l; 93% vs. 75%, p < 0.001) or the new Joint British Societies (JBS 2) goal of LDL-C < 2.0 mmol/l (49.3% vs. 11.1%, p < 0.001). Ezetimibe 45-54 component of oligomeric golgi complex 2 Homo sapiens 108-113 16970214-0 2006 Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial. Ezetimibe 17-26 component of oligomeric golgi complex 2 Homo sapiens 91-126 16970214-1 2006 OBJECTIVE: To examine whether the improvements in lipid profiles and low-density lipoprotein cholesterol (LDL-C) goal attainment found in the Ezetimibe Add-On to Statin for Effectiveness trial occurred equally in the black, Hispanic, and white patient populations enrolled in the study. Ezetimibe 142-151 component of oligomeric golgi complex 2 Homo sapiens 106-111 16970214-8 2006 Ezetimibe added to statin therapy also statistically significantly (P < .001) increased the percentage of patients attaining their LDL-C goal for their National Cholesterol Education Program Adult Treatment Panel III risk category in black (63.0%), Hispanic (64.8%), and white (72.3%) patients compared with placebo plus statin (32.9% black patients, 19.0% Hispanic patients, and 19.7% white patients). Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 134-139 16970214-12 2006 CONCLUSION: Ezetimibe added to statin therapy is effective and well tolerated for improving the lipid profile and LDL-C goal attainment of patients regardless of race or ethnicity. Ezetimibe 12-21 component of oligomeric golgi complex 2 Homo sapiens 114-119 16893434-4 2006 At 6 weeks, ezetimibe 10 mg-simvastatin 20 mg provided a mean additional LDL-C reduction of 14.6% (95% CI 10.1-19.1) compared with simvastatin monotherapy (p < 0.0001). Ezetimibe 12-21 component of oligomeric golgi complex 2 Homo sapiens 73-78 16893434-5 2006 Moreover, a higher proportion of patients on ezetimibe/simvastatin achieved the National Standard Framework LDL-C standard (<3.0 mmol/l; 93% vs. 75%, p < 0.001) or the new Joint British Societies (JBS 2) goal of LDL-C < 2.0 mmol/l (49.3% vs. 11.1%, p < 0.001). Ezetimibe 45-54 component of oligomeric golgi complex 2 Homo sapiens 218-223 16893434-6 2006 On logistic regression analysis, the odds ratio of achieving target LDL-C with ezetimibe 10 mg-simvastatin 20 mg was 5.1 (95% CI 1.8-15.0) times higher than with simvastatin monotherapy (p = 0.003). Ezetimibe 79-88 component of oligomeric golgi complex 2 Homo sapiens 68-73 16534487-5 2006 As a result, ezetimibe has been added to patients with persistently elevated triglycerides and/or LDL-c in individuals who possessed a renal transplant and were deemed to be on a maximum safe dose of statin agent. Ezetimibe 13-22 component of oligomeric golgi complex 2 Homo sapiens 98-103 16858759-6 2006 As expected from the improvement in TC and LDLC, more patients achieved recognised cholesterol targets after ezetimibe use. Ezetimibe 109-118 component of oligomeric golgi complex 2 Homo sapiens 43-47 16534487-6 2006 After the addition of ezetimibe, total cholesterol, LDL-c, and triglycerides fell by 21%, 31%, and 13%, respectively. Ezetimibe 22-31 component of oligomeric golgi complex 2 Homo sapiens 52-57 16574035-8 2006 The LDL-C-lowering efficacy of targeting both major sources of cholesterol with ezetimibe plus simvastatin was demonstrated in several multicentre, double-blind, placebo-controlled trials in patients with hypercholesterolaemia. Ezetimibe 80-89 component of oligomeric golgi complex 2 Homo sapiens 4-9 16574035-9 2006 For patients who do not reach their cholesterol goal with a statin, adding ezetimibe 10 mg significantly reduces LDL-C compared with statin monotherapy. Ezetimibe 75-84 component of oligomeric golgi complex 2 Homo sapiens 113-118 16297596-0 2005 Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Ezetimibe 99-108 component of oligomeric golgi complex 2 Homo sapiens 59-74 16297596-3 2005 To test the hypothesis that genetic variation in NPC1L1 could influence the LDL-C response to ezetimibe, we performed extensive resequencing of the gene in 375 apparently healthy individuals and genotyped hypercholesterolemic patients from clinical trial cohorts. Ezetimibe 94-103 component of oligomeric golgi complex 2 Homo sapiens 76-81 16297596-5 2005 However, significant associations to LDL-C response to treatment with ezetimibe were observed in patients treated with ezetimibe in two large clinical trials. Ezetimibe 70-79 component of oligomeric golgi complex 2 Homo sapiens 37-42 16297596-5 2005 However, significant associations to LDL-C response to treatment with ezetimibe were observed in patients treated with ezetimibe in two large clinical trials. Ezetimibe 119-128 component of oligomeric golgi complex 2 Homo sapiens 37-42 15969896-7 2005 In clinical studies, ezetimibe 10 mg, in combination with statins or as monotherapy, was well tolerated and reduced LDL-C by 34-53% and 17-18%, respectively. Ezetimibe 21-30 component of oligomeric golgi complex 2 Homo sapiens 116-121 16400393-4 2005 In general, the use of ezetimibe alone promotes modest effects on plasma LDL-c, however, when combined with statins, a remarkable change in the lipid profile can be observed. Ezetimibe 23-32 component of oligomeric golgi complex 2 Homo sapiens 73-78 16030077-2 2005 CASE SUMMARY: Ezetimibe 10 mg/day was added to the lipid-lowering regimen (atorvastatin 40 mg/day) of a 64-year-old male patient after OHT to achieve a target low-density lipoprotein cholesterol (LDL-C) level < or = 97 mg/dL, as recommended by national guidelines. Ezetimibe 14-23 component of oligomeric golgi complex 2 Homo sapiens 159-194 16030077-2 2005 CASE SUMMARY: Ezetimibe 10 mg/day was added to the lipid-lowering regimen (atorvastatin 40 mg/day) of a 64-year-old male patient after OHT to achieve a target low-density lipoprotein cholesterol (LDL-C) level < or = 97 mg/dL, as recommended by national guidelines. Ezetimibe 14-23 component of oligomeric golgi complex 2 Homo sapiens 196-201 16030077-3 2005 After 2 months of ezetimibe, the patient"s LDL-C level had decreased by 60% to 51 mg/dL. Ezetimibe 18-27 component of oligomeric golgi complex 2 Homo sapiens 43-48 16030077-4 2005 Subsequently, the dose of ezetimibe was reduced to 5 mg/day and, after another 2 months, a repeat lipid panel revealed LDL-C 57 mg/dL. Ezetimibe 26-35 component of oligomeric golgi complex 2 Homo sapiens 119-124 16030077-9 2005 An objective causality assessment in this case revealed that this supratherapeutic LDL-C reduction was probably related to coadministration of ezetimibe and cyclosporine. Ezetimibe 143-152 component of oligomeric golgi complex 2 Homo sapiens 83-88 16369229-0 2005 LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. Ezetimibe 27-36 component of oligomeric golgi complex 2 Homo sapiens 0-5 15864235-2 2005 This study tested the hypothesis that ezetimibe/simvastatin, a lipid-lowering agent that inhibits both intestinal cholesterol absorption and cholesterol synthesis, provides greater LDL-C reductions than atorvastatin across dose ranges. Ezetimibe 38-47 component of oligomeric golgi complex 2 Homo sapiens 181-186 15864235-11 2005 CONCLUSIONS: Ezetimibe/simvastatin was more effective than atorvastatin in lowering LDL-C at each dose comparison and provided greater increases in HDL-C at the 40- and 80-mg statin dose. Ezetimibe 13-22 component of oligomeric golgi complex 2 Homo sapiens 84-89 15864235-5 2005 RESULTS: At each milligram-equivalent statin dose comparison, and averaged across doses, ezetimibe/simvastatin provided greater LDL-C reductions (47%-59%) than atorvastatin (36%-53%). Ezetimibe 89-98 component of oligomeric golgi complex 2 Homo sapiens 128-133 15864235-7 2005 More ezetimibe/simvastatin than atorvastatin patients with coronary heart disease (CHD) or CHD risk equivalents attained the ATP III LDL-C goal of <100 mg/dL and the optional LDL-C target of <70 mg/dL. Ezetimibe 5-14 component of oligomeric golgi complex 2 Homo sapiens 133-138 15864235-7 2005 More ezetimibe/simvastatin than atorvastatin patients with coronary heart disease (CHD) or CHD risk equivalents attained the ATP III LDL-C goal of <100 mg/dL and the optional LDL-C target of <70 mg/dL. Ezetimibe 5-14 component of oligomeric golgi complex 2 Homo sapiens 178-183 15239487-14 2004 Ezetimibe selectively blocks cholesterol absorption and lowers plasma LDL-C levels by an average of 18%. Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 70-75 15383192-2 2004 RESEARCH DESIGN AND METHODS: This was a post-hoc analysis of data from a randomized, double-blind, placebo-controlled trial designed to evaluate the low-density lipoprotein cholesterol (LDL-C)-lowering efficacy and safety of adding ezetimibe 10 mg/day versus placebo to ongoing, open-label statin treatment for 8 weeks in hypercholesterolemic patients. Ezetimibe 232-241 component of oligomeric golgi complex 2 Homo sapiens 186-191 15383192-11 2004 Significantly more ezetimibe than placebo patients in all subgroups achieved prespecified LDL-C goals (p < 0.001 for all), and although more patients in the DM and MetS groups, respectively, achieved the goal compared with their non-DM and non-MetS counterparts [83.6% (DM) versus 67.2 (non-DM) and 71.8% (MetS) versus 65.6% (non-MetS)], these differences were not significant after adjusting for differences in baseline LDL-C levels. Ezetimibe 19-28 component of oligomeric golgi complex 2 Homo sapiens 90-95 15383192-11 2004 Significantly more ezetimibe than placebo patients in all subgroups achieved prespecified LDL-C goals (p < 0.001 for all), and although more patients in the DM and MetS groups, respectively, achieved the goal compared with their non-DM and non-MetS counterparts [83.6% (DM) versus 67.2 (non-DM) and 71.8% (MetS) versus 65.6% (non-MetS)], these differences were not significant after adjusting for differences in baseline LDL-C levels. Ezetimibe 19-28 component of oligomeric golgi complex 2 Homo sapiens 424-429 15383192-13 2004 CONCLUSIONS: The co-administration of ezetimibe with statins, a therapeutic regimen that inhibits both the absorption and synthesis of cholesterol, offers a well-tolerated and efficacious treatment to lower LDL-C in patients with DM and MetS. Ezetimibe 38-47 component of oligomeric golgi complex 2 Homo sapiens 207-212 15132403-6 2004 RESULTS: Coadministration of ezetimibe/simvastatin was significantly (P<.001) more effective than simvastatin alone in reducing LDL-C levels for the pooled ezetimibe/simvastatin vs pooled simvastatin analysis and at each specific dose comparison. Ezetimibe 29-38 component of oligomeric golgi complex 2 Homo sapiens 131-136 15132403-7 2004 The decrease in LDL-C levels with coadministration of ezetimibe and the lowest dose of simvastatin, 10 mg, was similar to the decrease with the maximum dose of simvastatin, 80 mg. A significantly (P<.001) greater proportion of patients in the ezetimibe/simvastatin group achieved target LDL-C levels compared with those in the monotherapy group. Ezetimibe 54-63 component of oligomeric golgi complex 2 Homo sapiens 16-21 15132403-7 2004 The decrease in LDL-C levels with coadministration of ezetimibe and the lowest dose of simvastatin, 10 mg, was similar to the decrease with the maximum dose of simvastatin, 80 mg. A significantly (P<.001) greater proportion of patients in the ezetimibe/simvastatin group achieved target LDL-C levels compared with those in the monotherapy group. Ezetimibe 54-63 component of oligomeric golgi complex 2 Homo sapiens 290-295 12773075-9 2003 In clinical trials, ezetimibe 10 mg/d reduced low-density lipoprotein cholesterol (LDL-C) by approximately 18% and further enhanced the LDL-C-lowering effect of statin medications by an additional 15-20%. Ezetimibe 20-29 component of oligomeric golgi complex 2 Homo sapiens 46-81 15161326-12 2004 Ezetimibe is a selective cholesterol absorption inhibitor, which produces reductions in LDL-C of up to 25 and 60% reduction in chylomicron cholesterol content with a 10 mg/day dosage. Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 88-93 12773075-9 2003 In clinical trials, ezetimibe 10 mg/d reduced low-density lipoprotein cholesterol (LDL-C) by approximately 18% and further enhanced the LDL-C-lowering effect of statin medications by an additional 15-20%. Ezetimibe 20-29 component of oligomeric golgi complex 2 Homo sapiens 83-88 12773075-9 2003 In clinical trials, ezetimibe 10 mg/d reduced low-density lipoprotein cholesterol (LDL-C) by approximately 18% and further enhanced the LDL-C-lowering effect of statin medications by an additional 15-20%. Ezetimibe 20-29 component of oligomeric golgi complex 2 Homo sapiens 136-141 12719279-6 2003 Coadministration of ezetimibe provided a significant additional 12% LDL-C reduction, 3% HDL-C increase, 8% triglyceride reduction, and 10% hs-CRP reduction versus atorvastatin alone. Ezetimibe 20-29 component of oligomeric golgi complex 2 Homo sapiens 68-73 12839042-8 2003 Clinical studies indicate that ezetimibe effectively decreases LDL-C by 15 to 20% as monotherapy, with a favorable safety profile. Ezetimibe 31-40 component of oligomeric golgi complex 2 Homo sapiens 63-68 12719279-5 2003 Ezetimibe plus atorvastatin significantly improved LDL-C, HDL cholesterol (HDL-C), triglycerides, total cholesterol:HDL-C, and high-sensitivity C-reactive protein (hs-CRP) compared with atorvastatin alone (P<0.01). Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 51-56 12719279-7 2003 Ezetimibe plus atorvastatin provided LDL-C reductions of 50% to 60%, triglyceride reductions of 30% to 40%, and HDL-C increases of 5% to 9%, depending on atorvastatin dose. Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 37-42 12719279-8 2003 LDL-C reductions with ezetimibe plus 10 mg atorvastatin (50%) and 80 mg atorvastatin alone (51%) were similar. Ezetimibe 22-31 component of oligomeric golgi complex 2 Homo sapiens 0-5 12719279-10 2003 When coadministered with atorvastatin, ezetimibe provided significant incremental reductions in LDL-C and triglycerides and increases in HDL-C. Coadministration of ezetimibe and atorvastatin offers a well-tolerated and highly efficacious new treatment option for patients with hypercholesterolemia. Ezetimibe 39-48 component of oligomeric golgi complex 2 Homo sapiens 96-101 14613354-10 2003 Phase 2 data demonstrated that ezetimibe lowers LDL-C by 18% and has a tolerability and short-term safety profile similar to placebo. Ezetimibe 31-40 component of oligomeric golgi complex 2 Homo sapiens 48-53 14613355-9 2003 This paper reviews the pharmacotherapeutic effects of combination therapy, summarizes the strengths and weaknesses of current lipid-lowering drug combinations, and identifies the potential contribution of the novel cholesterol absorption inhibitor, ezetimibe, to the LDL-C treatment algorithm. Ezetimibe 249-258 component of oligomeric golgi complex 2 Homo sapiens 267-272 12437505-1 2002 Ezetimibe is a cholesterol absorption inhibitor that significantly lowers low- density lipoprotein cholesterol (LDL-C), and favourably affects triglyceride and high-density lipoprotein cholesterol blood levels in monotherapy and in combination with statins. Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 112-117 11777299-6 2001 Ezetimibe, the first selective cholesterol absorption inhibitor, has been shown to lower LDL-C by approximately 18% following a once-daily 10 mg dose, either as monotherapy or as combination therapy. Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 89-94 11777299-7 2001 Combination therapy with selective cholesterol absorption inhibitors such as ezetimibe along with statins or fibrates may allow more patients with hypercholesterolaemia to achieve target LDL-C levels compared with treatment with monotherapy. Ezetimibe 77-86 component of oligomeric golgi complex 2 Homo sapiens 187-192 11558859-5 2001 The 5- and 10-mg doses of ezetimibe significantly reduced LDL-C levels by 15.7% and 18.5%, respectively (P < 0.01 vs placebo) and significantly increased high-density lipoprotein cholesterol (hDL-C) levels by 2.9% and 3.5%, respectively (P < 0.05 vs placebo). Ezetimibe 26-35 component of oligomeric golgi complex 2 Homo sapiens 58-63 11549098-0 2001 The plasma concentration and LDL-C relationship in patients receiving ezetimibe. Ezetimibe 70-79 component of oligomeric golgi complex 2 Homo sapiens 29-34 11549098-1 2001 Ezetimibe is a novel selective inhibitor of intestinal cholesterol absorption, which has been shown to significantly decrease low-density lipoprotein cholesterol (LDL-C). Ezetimibe 0-9 component of oligomeric golgi complex 2 Homo sapiens 163-168 11549098-2 2001 In this article, the relationship between plasma ezetimibe concentrations and lowering of LDL-C is determined using Emax and regression models. Ezetimibe 49-58 component of oligomeric golgi complex 2 Homo sapiens 90-95 11558859-7 2001 With the 10-mg dose of ezetimibe, 67.8% of patients achieved > or = 15% reduction in plasma LDL-C levels, and 22.0% achieved > or = 25% reduction. Ezetimibe 23-32 component of oligomeric golgi complex 2 Homo sapiens 95-100 11558859-9 2001 The decrease in plasma LDL-C levels was significantly greater with ezetimibe 10 mg compared with ezetimibe 5 mg (P < 0.05). Ezetimibe 67-76 component of oligomeric golgi complex 2 Homo sapiens 23-28 11558859-9 2001 The decrease in plasma LDL-C levels was significantly greater with ezetimibe 10 mg compared with ezetimibe 5 mg (P < 0.05). Ezetimibe 97-106 component of oligomeric golgi complex 2 Homo sapiens 23-28